Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2485-2495

  Bratton, Emily W ^a   Husseini, Nada El ^b   Chastain, Cody A ^b,d   Lee, Michael S ^b,e   Poole, Charles ^a   Stürmer, Til ^a   Weber, David J ^a,c   Juliano, Jonathan J ^c   Perfect, John R ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ADULT; ARTICLE; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84877851564     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01800-12     Document Type: Article

References (35)

1. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
2. Jackson A, Hosseinipour MC. 2010. Management of cryptococcal meningitis in sub-Saharan Africa. Curr. HIV/AIDS Rep. 7:134-142.
3. Jarvis JN, Dromer F, Harrison TS, Lortholary O. 2008. Managing cryptococcosis in the immunocompromised host. Curr. Opin. Infect. Dis. 21:596-603.
4. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
5. Warkentien T, Crum-Cianflone NF. 2010. An update on Cryptococcus among HIV-infected patients. Int. J. STD AIDS 21:679-684.
6. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 301:126-131.
7. Casadevall A, Perfect Jr. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
8. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. 2007. Determinants of disease presentation and outcome during cryptococcosis: The CryptoA/D study. PLoS Med. 4:e21. doi:10.1371/journal.pmed .0040021.
9. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.N. Engl. J. Med. 326:83-89.
10. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337:15-21.
11. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L. 1996. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: Retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin. Infect. Dis. 22(Suppl 2):S154-S60.
12. McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo N, Moeng P, Maloba BR, Crewe-Brown HH, Brandt ME, Hajjeh RA. 2006. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 20:2199-2206.
13. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC, Kontoyiannis DP, Morris AJ, Heath CH, Wagener M, Yu VL. 2010. Outcomes of central nervous system cryptococcosis vary with host immune function: Results from a multi-center, prospective study. J. Infect. 61:419-426.
14. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ, Holloway MS, Warren RM, Dismukes WE. 2001. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33:690-699.
15. World Health Organization. 1977. Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision. World Health Organization, Geneva, Switzerland.
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. 2009. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150: 604-612.
17. Singh N, Perfect Jr. 2007. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect. Dis. 7:395-401.
18. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, Stürmer T, Juliano JJ, Weber DJ, Perfect Jr. 2012. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 7:e43582.
19. Knuppel S, Stang A. 2010. DAG program: Identifying minimal sufficient adjustment sets. Epidemiology 21:159.
20. Darras-Joly C, Chevret S, Wolff M, Longuet P, Casalino E, Joly V, Chochillon C, Bedos JP. 1996. Cryptococcus neoformans infection in France: Epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin. Infect. Dis. 23:369-376.
21. Diamond RD, Bennett JE. 1974. Prognostic factors in cryptococcal meningitis. Ann. Intern. Med. 80:176-181.
22. Dismukes WE, Cloud G, Gallis H, Kerkering TM, Medoff G, Craven PL, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, Shadomy S, Stamm AM, Diasio RB, Kaufman L, Soon SJ, Blackwelder W, The National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1987. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 317:334-341.
23. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE, the Mycoses Study Group Cryptococcal Subproject. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30:710-718.
24. Witt MD, Lewis RJ, Larsen RA, Milefichik EN, Leal MAE, Haubrich RH, Richie JA, Edwards JE, Ghannoum MA. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin. Infect. Dis. 22:322-328.
25. Rothman KJ, Greenland S, Lash TL. 2008. Modern epidemiology, 3rd ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA.
26. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. 2005. Calculating measures of biological interaction. Eur. J. Epidemiol. 20:575-579.
27. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30:47-54.
28. Chayakulkeeree M, Perfect Jr. 2006. Cryptococcosis. Infect. Dis. Clin. North Am. 20:507-544, v-vi.
29. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet 363:1764-1767.
30. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, Teparrakkul P, Loyse A, White NJ, Wood R, Jaffar S, Harrison T. 2009. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23:701-706.
31. Day JN, Chau TTH, Mai PP, Dung NT, Mai NH, Phu NH. 2011. Combination antifungal therapy reduces mortality in severe cryptococcal meningitis, abstr M-1141a. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
32. Bicanic T, Harrison TS. 2004. Cryptococcal meningitis. Br. Med. Bull. 72:99-118.
33. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker LG, Jaffar S, Harrison T. 2008. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial. Clin. Infect. Dis. 47:123-130.
34. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl 1): S5-S14.
35. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. 2008. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob. Agents Chemother. 52:735-738.